TDOC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

635.06M

-0.85%

-0.212

-13.3%

632.60M

+0.51%

-0.300

+37.11%

635.34M

+0.54%

-0.225

+52.75%

Estimates Revision

The market is revising Upward the revenue expectations for Teladoc Health, Inc. (TDOC) for FY2025, with the revenue forecasts being adjusted by 0.05% over the past three months. During the same period, the stock price has changed by -14.01%.

Revenue Estimates for FY2025

Revise Upward

+0.05%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-17.51%

In Past 3 Month

Stock Price

Go Down

-14.01%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 9.30 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

11 Hold

0 Sell

Hold

Current: 0.000

Low

8.00

Averages

9.30

High

12.00

Current: 0.000

Low

8.00

Averages

9.30

High

12.00

Goldman Sachs

David Roman

Buy

downgrade

$10 -> $9

2026-01-09

New

Reason

Goldman Sachs

David Roman

Price Target

$10 -> $9

2026-01-09

New

downgrade

Buy

Reason

Goldman Sachs analyst David Roman lowered the firm's price target on Teladoc to $9 from $10 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

BofA

Neutral

downgrade

2026-01-05

New

Reason

BofA

Price Target

2026-01-05

New

downgrade

Neutral

Reason

BofA lowered the firm's price target on Teladoc to $7.50 from $8 and keeps a Neutral rating on the shares. Heading into 2026, the firm maintains its positive view on the drug distributor group and updates its price targets to reflect peer group multiple changes.

Barclays

Equal Weight

initiated

$8.50

2025-12-08

Reason

Barclays

Price Target

$8.50

2025-12-08

initiated

Equal Weight

Reason

Barclays initiated coverage of Teladoc with an Equal Weight rating and $8.50 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.

BofA

Neutral

downgrade

$9 -> $8

2025-11-25

Reason

BofA

Price Target

$9 -> $8

2025-11-25

downgrade

Neutral

Reason

BofA lowered the firm's price target on Teladoc to $8 from $9 and keeps a Neutral rating on the shares. October BetterHelp MAUs are tracking above the Q3 average, but the firm remains cautious on near-term trends given it is early in Q4 and management's commentary that weaker consumer sentiment and macro uncertainties were consistent through Q3, the analyst tells investors.

BMO Capital

Sean Dodge

Market Perform

initiated

2025-11-12

Reason

BMO Capital

Sean Dodge

Price Target

2025-11-12

initiated

Market Perform

Reason

BMO Capital analyst Sean Dodge initiated coverage of Teladoc with a Market Perform rating and $8 price target. Teladoc remains the leading telehealth and virtual mental health provider, though growth has slowed since the pandemic, the analyst tells investors in a research note. Management's efforts to revive revenue show early promise, and greater adoption of BetterHelp through insurance, stabilization of U.S. cash-pay users, and sustained international momentum could strengthen the outlook, the firm says.

BofA

Neutral

maintain

2025-10-24

Reason

BofA

Price Target

2025-10-24

maintain

Neutral

Reason

BofA raised the firm's price target on Teladoc to $9 from $8.50 and keeps a Neutral rating on the shares after the company announced a CFO transition, reaffirmed its 2025 revenue and adjusted EBITDA outlook and provided preliminary Q3 results. The firm continues to view Teladoc as a differentiated asset given its broad scale and optionality from recent acquisitions, but remains cautious on the near-term outlook, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Teladoc Health Inc (TDOC.N) is -7.68, compared to its 5-year average forward P/E of -28.53. For a more detailed relative valuation and DCF analysis to assess Teladoc Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-28.53

Current PE

-7.68

Overvalued PE

-2.31

Undervalued PE

-54.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

28.71

Current EV/EBITDA

5.36

Overvalued EV/EBITDA

62.09

Undervalued EV/EBITDA

-4.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.41

Current PS

0.49

Overvalued PS

7.87

Undervalued PS

-1.05

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TDOC News & Events

Events Timeline

No data

News

9.5

01-04NASDAQ.COM

Teladoc Health Faces 92% Stock Decline Amid Intense Competition

9.5

01-04Fool

Teladoc Health Faces 92% Stock Decline Amidst Competition and Losses

9.5

2025-12-27NASDAQ.COM

Teladoc Reports 2% Revenue Decline, Plans Repositioning for 2025

People Also Watch

Frequently Asked Questions

What is Teladoc Health Inc (TDOC) stock price today?

The current price of TDOC is 7.61 USD — it has increased 0.53 % in the last trading day.

What is Teladoc Health Inc (TDOC)'s business?

Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.

What is the price predicton of TDOC Stock?

What is Teladoc Health Inc (TDOC)'s revenue for the last quarter?

Teladoc Health Inc revenue for the last quarter amounts to 626.44M USD, decreased -2.20 % YoY.

What is Teladoc Health Inc (TDOC)'s earnings per share (EPS) for the last quarter?

Teladoc Health Inc. EPS for the last quarter amounts to -0.28 USD, increased 47.37 % YoY.

What changes have occurred in the market's expectations for Teladoc Health Inc (TDOC)'s fundamentals?

How many employees does Teladoc Health Inc (TDOC). have?

Teladoc Health Inc (TDOC) has 5500 emplpoyees as of January 09 2026.

What is Teladoc Health Inc (TDOC) market cap?

Today TDOC has the market capitalization of 1.35B USD.